Comparison of Immune Responses and Safety Profiles Following a Fourth Heterologous Dose (Second Booster) with mRNA-1273 in Individuals Previously Vaccinated with Two Doses of CoronaVac and a Booster Dose of Either AZD1222 or BNT162b2
: A heterologous fourth mRNA-1273 booster in both 2CV/AZ- and 2CV/BNT-primed groups effectively enhances B-cell and T-cell responses against SARS-CoV-2. However, emerging variants such as Omicron may still pose challenges. The trial was registered with the Thai Clinical Trials Registry: the name of the registry: "The comparison of immune response to the 4th dose booster with mRNA-1273 COVID-19 vaccine in individuals who had received 2 doses of CoronaVac and booster with ChAdOx-1 or BNT162b2 COVID-19 vaccine", TCTR20220205002 on 5 February 2022.
Authors
- Phuntila Tharabenjasin (ORCID: https://orcid.org/0000-0002-4191-2802)
- Yamonbhorn Neamkul
- Kanokporn Thongphubeth
- Pornumpa Bunjoungmanee (ORCID: https://orcid.org/0000-0002-1285-7672)
- Arthit Boonyarangkul
- Auchara Tangsathapornpong (ORCID: https://orcid.org/0000-0001-7715-8744)
- Sira Nanthapisal (ORCID: https://orcid.org/0000-0003-3196-4657)
- Waraphon Fukpho
- Kanassanan Pontan
- Peera Jaru-Ampornpan (ORCID: https://orcid.org/0000-0002-4610-2235)
- Supattra Wanpen
Institutions
- Thammasat University (TH)
- Thammasat University Hospital (TH)
- National Center for Genetic Engineering and Biotechnology (TH)
Publication Details
- Journal
- Vaccines
- Published
- 2026-04-15
- DOI
- https://doi.org/10.3390/vaccines14040348
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Thammasat University